BioAdvance

BioAdvance is venture capital firm specializing in pre seed, seed, and start up investments. The firm seeks to invest in life sciences, therapeutic agents, diagnostics, health information technology, medical devices, research tools, and platform technologies focused on human health. It prefers to invest in Mid-Atlantic companies mainly based in the Southeastern region of Pennsylvania in the United States. The firm makes a maximum of $0.5 million equity investment. BioAdvance was founded in 2002 and is based in Radnor, Pennsylvania.

Robert Driscoll

Director of Finance

Gregory Harriman

Partner

Shahram Hejazi

MD and CEO

Frederick Jones

Partner

Marnie Mccoy

Program Director

Barbara S. Schilberg

Advisor and Former CEO

190 past transactions

Avid Radiopharmaceuticals

Seed Round in 2005
Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

Phrase Health

Seed Round in 2021
Phrase Health, Inc. provides software solutions for health care sector. The company was founded in 2018 and is based in Philadelphia, Pennsylvania.

Halo Labs

Seed Round in 2011
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Niiki Pharma

Venture Round in 2010
Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

RiboNova

Seed Round in 2016
RiboNova is a biomedical research company in the Lankenau Institute for Medical Research. The company develops a small molecule drugs against a new family of targets, defective transfer RNAs. Its focus is on novel therapies for the treatment of serious rare diseases, including mitochondrial disease and certain cancers.

Mebias Discovery, LLC

Venture Round in 2016
Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Acuity Pharmaceuticals

Series B in 2004
Acuity Pharmaceuticals is a pharmaceutical company that is focused on the treatment and prevention of ophthalmic diseases. It develops treatments for age-related macular degeneration and diabetic retinopathy. The company offers Cand5, a clinical compound that is able to shut down vascular endothelial growth factor. Acuity Pharmaceuticals was acquired by OPKO Health in June 2011. Acuity Pharmaceuticals was founded in 2007 and is based in Philadelphia, Pennsylvania.

Ride Health LLC

Series A in 2020
Ride Health LLC develops a SaaS product platform which enables healthcare providers to schedule, request, and pay for rides on behalf of patients to and from medical appointments. The platform allows coordinators to schedule patient rides in advance or on-demand, sends text message updates and reminders to patients throughout the process, and gives coordinators real-time insight on transportation costs and usage. Ride Health LLC was founded in 2016 and is based in New York, New York.

Palvella Therapeutics

Series C in 2020
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.

Formae

Seed Round in 2008
Formae, Inc. develops products in arthroscopic joint resurfacing and replacement. It offers ArthroPad, a biocompatible implant offering an arthroscopic minimally invasive surgical option to replace damaged cartilage in arthritic joints. The company serves applications, such as arthritis and joint destructions. Formae, Inc. was founded in 2006 and is based in Paoli, Pennsylvania.

Cohero Health

Venture Round in 2016
Cohero Health offers a proprietary connected health platform for those with respiratory illness. Its sensor-based technology and engaging platform improve medication adherence and care coordination between patients and their care providers. The company offers a suite of tools and technology comprises form flexible inhaler sensors, mobile spirometers, to track real-time adherence and lung function, and a mobile application accessible on iPhone, iWatch, and Android. Cohero Health was founded in 2013 and is headquartered in New York.

InfraScan

Seed Round in 2008
InfraScan, Inc., a medical device company, develops, commercializes, and distributes hand-held diagnostic devices for head injury and stroke assessment based on near-infrared (NIR) technology. It offers Infrascanner, a diagnostic device that enables clinicians to detect intracranial bleeding in patients with head trauma; and education and training services. The company’s device is used in hospital and intensive care monitoring, military, screening in remote areas, sports medicine, pediatrics, ambulance services, and other applications. It sells its products through distributors in North America, South America, Africa, Asia, the Middle East, and Europe. InfraScan, Inc. was incorporated in 2004 and is based in Philadelphia, Pennsylvania with research and development lab in Philadelphia, Pennsylvania.

Bainbridge Health

Seed Round in 2018
Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.

Phoenix S&T, Inc.

Seed Round in 2008
Phoenix S&T, Inc. designs, develops, and supplies nanospray and microspray systems for life research and drug discovery solutions. The company’s Nimbus and pneu-Nimbus NanoLC systems provide ionization for LC/MS experiments; clinical diagnostics; and homeland security. It offers column haters, column coolers, and emitters and columns. The company’s products are used in various applications, including proteomics, biomarkers, and direct infusion. It serves customers in Europe and China. The company was founded in 2001 and is based in Chadds Ford, Pennsylvania.

Ceptaris Therapeutics

Series B in 2006
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Marillion Pharmaceuticals

Venture Round in 2007
Marillion Pharmaceuticals Inc. develops and commercializes pharmaceuticals and therapeutics for the treatment of cancers, inflammatory, and autoimmune diseases.

Niiki Pharma

Venture Round in 2012
Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

Novira Therapeutics, Inc.

Seed Round in 2009
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Jenrin Discovery, Inc.

Venture Round in 2010
Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

EyeIC, Inc.

Seed Round in 2005
EyeIC, Inc. develops and commercializes imaging technologies for medical applications. The company serves eye care professionals and eye clinics. It offers MatchedFlicker, a device for monitoring the advent and progression of glaucoma through change detection in time series retinal photographs. The company's software works by aligning and registering two images of the same object taken at different points in time, and then generating a superimposed view that is alternated back and forth. The company was founded in 2004 and is based in Wayne, Pennsylvania.

Halo Labs

Series C in 2022
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Opsidio

Venture Round in 2017
A biotech company, engages in developing monoclonal antibodies to treat fibrotic and remodeling diseases. The company was founded in 2012 and is headquartered in Bryn Mawr, Pennsylvania .

Noble.MD

Seed Round in 2016
Noble.MD develops Theo, a digital healthcare advisory platform that helps patients to identify health and behavioral risks, and activate patients to manage those risks through programs and interventions. The company’s platform captures patient data required for value-based reimbursement at the time-of-care; and aligns provider and payer interests to accelerate risk identification, coding, and management. Noble.MD was founded in 2012 and is based in Bryn Mawr, Pennsylvania.

KayoThera

Series A in 2022
KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is to develop the first-in-class immuno- and targeted therapies to drive cures in advanced cancers KayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.

Novira Therapeutics, Inc.

Seed Round in 2010
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Halo Labs

Series B in 2018
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Jenrin Discovery, Inc.

Venture Round in 2014
Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

Merganser Biotech

Series A in 2014
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

Alteris Therapeutics Inc.

Seed Round in 2003
Alteris Therapeutics, Inc. engages in the discovery and development of therapeutics and vaccines based on alternative gene splice forms for the treatment of cancer. Its compound, ALT-110, a therapeutic vaccine against the splice variant growth factor EGFRvIII, is currently being tested in a Phase I cancer trial. The company also has a drug discovery program, which targets tumors, including breast, colon, lung, ovarian, and central nervous system cancers. Alteris Therapeutics, formerly known as Spliceomix, Inc., was founded in 2002 and is based in Philadelphia, Pennsylvania. As of October 12, 2005, Alteris Therapeutics Inc. is a subsidiary of Celldex Therapeutics Inc.

WellSheet, Inc.

Seed Round in 2017
Wellsheet organizes clinical information with machine learning to predict and visualize the most relevant information for patient care in a physician-friendly format within the existing EHR (Electronic Health Record). By allowing providers to arrive at clinical insights faster, Wellsheet improves early intervention and hospital efficiency, with proven impact in a 10,000 physician health system in NJ. Wellsheet has partnered with major EHR vendors including Epic and Cerner to distribute the Wellsheet product through SaaS-based model for health system customers.

Ceptaris Therapeutics

Debt Financing in 2010
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Cira Discovery Sciences

Seed Round in 2004
Cira Discovery Sciences creates new advanced algorithmic methods for analyzing High Dimensional Biology. The increasing availability of high-quality data from "-omics" methodologies represents an opportunity to create value for Life Sciences enterprises.

HealthQx

Series B in 2015
HealthQX specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its VBP analytics platform, ClarityQx, provides the capabilities to design, implement, and monitor the on-going performance of payment models such as episodic, bundled, or accountable care arrangements. The company was founded in 2012 and is based in King Of Prussia, Pennsylvania.

Life Mist Technologies

Seed Round in 2013
Life Mist Technologies, Inc., doing business as LMT, develops and commercializes an atomization technology that uses low pressure gas and liquid to produce a high volume of micron sized droplets. The company focuses on using its technology in various industrial applications, such as aircraft fire suppression, chemical processing, emission control, fire suppression, decontamination, turbine inlet cooling, artificial snow, and cooling. Life Mist Technologies was incorporated in 2004 and is based in Paoli, Pennsylvania.

PhenoTech, Inc.

Seed Round in 2004
PhenoTech a biotechnology company, engages in the discovery, development, and commercialization of reagents for diagnostic use in blood banks. The company offers blood diagnostic reagents, such as Nanoscale Emissive Antibody-complexes for Typing reagents for pre-transfusion testing. It also provides therapeutic agents, including a series of human-like monoclonal antibodies for treatment of Idiopathic Thrombocytopenic Purpura, an autoimmune disorder in the field of hematology; and anti-platelet agents, such as Infusable gpIIb/IIIa antagonist agents that are used after acute myocardial infarction, as well as in patients undergoing balloon angioplasty or stent placement in order to prevent cardiac ischemic complications.

Enzium, Inc.

Venture Round in 2016
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

Phrase Health

Pre Seed Round in 2019
Phrase Health, Inc. provides software solutions for health care sector. The company was founded in 2018 and is based in Philadelphia, Pennsylvania.

Novira Therapeutics, Inc.

Venture Round in 2010
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Immunome

Venture Round in 2014
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

Cool-Bio

Seed Round in 2012
COOL~BIO is a biotechnology company focused on developing hypothermia-activated biologics. Therapeutic hypothermia (TH) is the process of cooling the body to prevent organ damage and is widely-used in cardiac surgery, ischemic stroke, cardiac arrest, neurosurgery and traumatic brain injury. Their lead molecule is an anti-platelet agent being developed for use during cardiopulmonary bypass.

NuPathe, Inc.

Series A in 2006
NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for neurological and psychiatric disorders. The company’s lead product is Zecuity, which is a sumatriptan iontophoretic transdermal system used for the acute treatment of migraine with or without aura in adults. Its pipeline product candidates include NP201 for the continuous symptomatic treatment of Parkinson's disease; and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The company develops its products using SmartRelief, a proprietary transdermal medication delivery technology based on iontophoresis, a non-invasive method of actively transporting molecules, such as sumatriptan; and Long-Acting Delivery, a biodegradable polymer matrix, which uses medical polymers and an active drug combined to form a small implant for injection just below the skin. NuPathe Inc. was founded in 2005 and is based in Malvern, Pennsylvania. As of February 20, 2014, NuPathe, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.

VenatoRx Pharmaceuticals, Inc.

Venture Round in 2013
VenatoRx Pharmaceuticals, Inc., a pharmaceutical company, discovers and develops anti-infective agents. The company provides various antibacterial agents. It focuses on addressing resistant hospital and community bacterial infections, including difficult-to-treat infections caused by MRSA, Pseudomonas spp, and Salmonella spp. The company was founded in 2010 and is based in Malvern, Pennsylvania.

InfraScan

Seed Round in 2005
InfraScan, Inc., a medical device company, develops, commercializes, and distributes hand-held diagnostic devices for head injury and stroke assessment based on near-infrared (NIR) technology. It offers Infrascanner, a diagnostic device that enables clinicians to detect intracranial bleeding in patients with head trauma; and education and training services. The company’s device is used in hospital and intensive care monitoring, military, screening in remote areas, sports medicine, pediatrics, ambulance services, and other applications. It sells its products through distributors in North America, South America, Africa, Asia, the Middle East, and Europe. InfraScan, Inc. was incorporated in 2004 and is based in Philadelphia, Pennsylvania with research and development lab in Philadelphia, Pennsylvania.

Cira Discovery Sciences

Seed Round in 2004
Cira Discovery Sciences creates new advanced algorithmic methods for analyzing High Dimensional Biology. The increasing availability of high-quality data from "-omics" methodologies represents an opportunity to create value for Life Sciences enterprises.

Cytovas

Venture Round in 2017
CytoVas LLC develops informatics platform that provides information on novel cellular markers of disease progression and individual treatment response to clinicians and drug developers. The company's platforms include CLOUD CYTOMICS and CytoVas Vascular Health Profile. CLOUD CYTOMICS provides automated data collection, mining, and modeling solutions to clinical researchers. CytoVas Vascular Health Profile provides cytometric vascular health event detection test for clinical studies. The company was incorporated in 2010 and is headquartered in Philadelphia, Pennsylvania.

Jenrin Discovery, Inc.

Venture Round in 2016
Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

Niiki Pharma

Venture Round in 2011
Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

Midway Pharmaceuticals

Seed Round in 2006
Midway Pharmaceuticals is a developer of specialty drugs designed to provide beneficial effects in the treatment of gastrointestinal and systemic diseases. The company's specialty drugs focus on finding high molecular weight polymers that can be consumed orally and inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing, enabling healthcare institutions to avail enhanced drugs to protect people's guts from radiation damage and infection.

Innovative Supply Solutions

Venture Round in 2012
Innovative Supply Solutions LLC, a specialty contract service organization, provides clinical drug supply chain management services. Its services include planning/forecasting for API/formulated product needs, project management, budget projection/management, packaging design, inventory management, supply chain coordination and management, IVR/IWR supply design and management, manufacturing coordination, packaging and labeling coordination, distribution coordination, analytical services coordination, product sourcing, material destruction coordination, and consultancy. The company is based in Southampton, Pennsylvania.

Penn-Greene

Seed Round in 2011
Penn-Greene

Immunome

Series A in 2016
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

Ceptaris Therapeutics

Venture Round in 2010
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Genome Profiling, LLC

Venture Round in 2017
Genome Profiling, LLC, a bioinformatics company, engages in the discovery of novel epigenetic biomarkers for treating diagnosing, and predicting chronic and life-threatening diseases. It offers GenPro Analytics, a software platform to discover novel epigenetic biomarkers that scientists and medical professionals use to predict, diagnose, and monitor the likelihood and progression of disease in individuals with more sensitivity, specificity, accuracy, and cost-effectiveness. The company was incorporated in 2012 and is based in Wayne, Pennsylvania.

Galleon Pharmaceuticals, Inc.

Venture Round in 2012
Galleon Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets treatments for sleep apnea and related breathing control disorders. It offers GAL-021, a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients and patients with sleep apnea; GLN- 21,160, an oral development candidate for sleep apnea; and GAL-044, a small molecule used as a preventative medicine for surgical pain. The company was founded in 2003 and is based in Horsham, Pennsylvania.

Gelifex

Seed Round in 2003
Gelifex develops implants for use in relieving pain and restoring motion to patients suffering from degenerative disc disease.

Treventis

Seed Round in 2009
TREVENTIS™ Corporation is an early stage biotechnology company focused on diseases associated with protein misfolding such as Alzheimer’s, Parkinson’s and Huntington’s. Currently, the Company has two major areas of discovery and development including: (1) the development of drugs that halt Alzheimer’s disease (and other dementias) progression with the promise of stabilizing or improving cognition and (2) the development of companion diagnostics for detection of AD to allow for early drug intervention to minimize neuronal loss.

Vasculab

Seed Round in 2005
Vasculab is a medical device company that is looking for a consulting Design Engineer.

Genome Profiling, LLC

Seed Round in 2016
Genome Profiling, LLC, a bioinformatics company, engages in the discovery of novel epigenetic biomarkers for treating diagnosing, and predicting chronic and life-threatening diseases. It offers GenPro Analytics, a software platform to discover novel epigenetic biomarkers that scientists and medical professionals use to predict, diagnose, and monitor the likelihood and progression of disease in individuals with more sensitivity, specificity, accuracy, and cost-effectiveness. The company was incorporated in 2012 and is based in Wayne, Pennsylvania.

Avid Radiopharmaceuticals

Series D in 2009
Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

Enzium, Inc.

Venture Round in 2015
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

Treventis

Seed Round in 2012
TREVENTIS™ Corporation is an early stage biotechnology company focused on diseases associated with protein misfolding such as Alzheimer’s, Parkinson’s and Huntington’s. Currently, the Company has two major areas of discovery and development including: (1) the development of drugs that halt Alzheimer’s disease (and other dementias) progression with the promise of stabilizing or improving cognition and (2) the development of companion diagnostics for detection of AD to allow for early drug intervention to minimize neuronal loss.

Mebias Discovery, LLC

Venture Round in 2017
Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Ride Health LLC

Seed Round in 2017
Ride Health LLC develops a SaaS product platform which enables healthcare providers to schedule, request, and pay for rides on behalf of patients to and from medical appointments. The platform allows coordinators to schedule patient rides in advance or on-demand, sends text message updates and reminders to patients throughout the process, and gives coordinators real-time insight on transportation costs and usage. Ride Health LLC was founded in 2016 and is based in New York, New York.

Novira Therapeutics, Inc.

Venture Round in 2010
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Formae

Seed Round in 2010
Formae, Inc. develops products in arthroscopic joint resurfacing and replacement. It offers ArthroPad, a biocompatible implant offering an arthroscopic minimally invasive surgical option to replace damaged cartilage in arthritic joints. The company serves applications, such as arthritis and joint destructions. Formae, Inc. was founded in 2006 and is based in Paoli, Pennsylvania.

NuPathe, Inc.

Series B in 2008
NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for neurological and psychiatric disorders. The company’s lead product is Zecuity, which is a sumatriptan iontophoretic transdermal system used for the acute treatment of migraine with or without aura in adults. Its pipeline product candidates include NP201 for the continuous symptomatic treatment of Parkinson's disease; and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The company develops its products using SmartRelief, a proprietary transdermal medication delivery technology based on iontophoresis, a non-invasive method of actively transporting molecules, such as sumatriptan; and Long-Acting Delivery, a biodegradable polymer matrix, which uses medical polymers and an active drug combined to form a small implant for injection just below the skin. NuPathe Inc. was founded in 2005 and is based in Malvern, Pennsylvania. As of February 20, 2014, NuPathe, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.

Sxinos

Seed Round in 2004
Sxinos Corporation is a Biotechnology company.

Olive Devices

Venture Round in 2017
Olive Devices is an assistive device company developing smart glasses to improve communication for deaf and hard of hearing persons.

SonoMedix

Seed Round in 2005
SonoMedix engages in the development and commercialization of technology designed for monitoring blood coagulation and hemostatic status. The company offers Nano-Acoustic Blood Analyzer platform (NABA) technology that helps to interrogate and detect blood properties at the molecular level. This product enables healthcare workers and patients to conduct diagnostic and therapeutic monitoring at the bedside and at home, using a small hand-held device.

Leversense

Debt Financing in 2010
Leversense, LLC intends to develop a medical device for detecting AIDS, food toxin, and mycoplasma bacteria. The company was incorporated in 2009 and is based in Newtown Square, Pennsylvania.

Enzium, Inc.

Seed Round in 2013
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

Jenrin Discovery, Inc.

Venture Round in 2010
Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

Vindico Medical Education

Seed Round in 2008
Vindico Medical Education is an accredited provider of CME, CE, and CNE multiplatform activities, offering the highest quality continuing education with the ultimate goal of improving patient health. Vindico facilitates accredited activities that positively affect clinical practice and provides quality initiatives for improving knowledge, competence, performance, and patient health. Vindico is solely dedicated to creating educational activities that provide healthcare professionals with evidence-based education on clinical advances to improve their competence, performance-in-practice, and ultimately to better treat their patients. Vindico provides scientifically sound and evidence-based activities in a variety of core therapeutic areas including cardiology, endocrinology, hematology/oncology, infectious diseases, ophthalmology, orthopedics, and pediatrics. Vindico employs an experienced team of physicians, scientists, educators, medical writers and editors, dedicated meeting managers, and an in-house design and recruitment department that ensure a seamless process from activity planning through delivery.

Neuro Innovations

Seed Round in 2008
Neuro Innovations

WellTrackONE, LLC

Venture Round in 2017
WellTrackONE is a population health management company that offers an end-to-end solution to physician offices, ACOs, integrated delivery networks, hospitals, and other physician networks that helps them administer the Medicare Annual Wellness Visit to all their Medicare patients. The company provides clinical risk management services used to offer a comprehensive baseline report for detailing modifiable risk factors, preventative goals, and measurable data. It was founded in 2012 and headquartered in Hilton Head Island, South Carolina.

Halo Labs

Seed Round in 2013
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Immunome

Seed Round in 2012
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

Eagle Vision Pharmaceutical

Seed Round in 2003
Eagle Vision Pharmaceutical Corp. offers a novel, clinical-stage, molecular imaging opportunity that enhances the powerful potential of widely available Magnetic Resonance Imaging (MRI) to revolutionize the diagnosis and management of chronic human disease (“Magnetic PET”). SeeMoreTM (EVP1001), a patented, first-in-class, intravenous, manganese-based, intracellular agent that targets metabolically active cells, capitalizes on the high resolution tissue discrimination of MRI to provide superior diagnostic accuracy and earlier assessment of response to therapy for improved patient management. EVP1001 distinguishes healthy from abnormal tissue in a single, noninvasive exam that avoids radiation and radioactive agents. Preclinical and clinical results have validated the technology for broad applications including evaluation of cancer, chronic liver disease and heart disease. Currently, a world-class medical center is conducting advanced clinical trials using EVP1001 to evaluate stem cell therapy for the heart.

Jenrin Discovery, Inc.

Venture Round in 2007
Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

Niiki Pharma

Seed Round in 2008
Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

ENB Therapeutics, Inc.

Series A in 2018
ENB Therapeutics, LLC develops small molecule inhibitors to treat melanoma and other cancers. The product includes ENB-001 that restores the ability of T-cells to infiltrate tumors and inhibits metastasis. The company was incorporated in 2015 and is based in New York, New York.

Protez Pharmaceuticals

Venture Round in 2004
Protez Pharmaceuticals is a medical research company that discovers, develops, and commercializes antibiotics for difficult-to-treat hospital-based infections. The company focuses on differentiated intravenous and oral small molecule antibiotics to address bacterial resistant, and chronic or recurrent infections. Protez Pharmaceuticals was founded by Christopher M. Cashman in 2003 and is headquartered in Malvern, Pennsylvania.

Phoenix S&T, Inc.

Debt Financing in 2010
Phoenix S&T, Inc. designs, develops, and supplies nanospray and microspray systems for life research and drug discovery solutions. The company’s Nimbus and pneu-Nimbus NanoLC systems provide ionization for LC/MS experiments; clinical diagnostics; and homeland security. It offers column haters, column coolers, and emitters and columns. The company’s products are used in various applications, including proteomics, biomarkers, and direct infusion. It serves customers in Europe and China. The company was founded in 2001 and is based in Chadds Ford, Pennsylvania.

Melior Discovery

Seed Round in 2005
Melior Discovery, Inc. develops an in vivo pharmacology platform that identifies novel indications from pre-clinical and development-stage candidates. The company offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal and urology, cardiovascular disease, and dermatology aspects. It serves clients in pharmaceutical and biopharmaceutical industries. The company was founded in 2005 and is based in Exton, Pennsylvania.

Innovative Supply Solutions

Seed Round in 2010
Innovative Supply Solutions LLC, a specialty contract service organization, provides clinical drug supply chain management services. Its services include planning/forecasting for API/formulated product needs, project management, budget projection/management, packaging design, inventory management, supply chain coordination and management, IVR/IWR supply design and management, manufacturing coordination, packaging and labeling coordination, distribution coordination, analytical services coordination, product sourcing, material destruction coordination, and consultancy. The company is based in Southampton, Pennsylvania.

Acuity Pharmaceuticals

Venture Round in 2004
Acuity Pharmaceuticals is a pharmaceutical company that is focused on the treatment and prevention of ophthalmic diseases. It develops treatments for age-related macular degeneration and diabetic retinopathy. The company offers Cand5, a clinical compound that is able to shut down vascular endothelial growth factor. Acuity Pharmaceuticals was acquired by OPKO Health in June 2011. Acuity Pharmaceuticals was founded in 2007 and is based in Philadelphia, Pennsylvania.

InfraScan

Seed Round in 2005
InfraScan, Inc., a medical device company, develops, commercializes, and distributes hand-held diagnostic devices for head injury and stroke assessment based on near-infrared (NIR) technology. It offers Infrascanner, a diagnostic device that enables clinicians to detect intracranial bleeding in patients with head trauma; and education and training services. The company’s device is used in hospital and intensive care monitoring, military, screening in remote areas, sports medicine, pediatrics, ambulance services, and other applications. It sells its products through distributors in North America, South America, Africa, Asia, the Middle East, and Europe. InfraScan, Inc. was incorporated in 2004 and is based in Philadelphia, Pennsylvania with research and development lab in Philadelphia, Pennsylvania.

Keriton LLC

Seed Round in 2017
Keriton LLC provides pumped breast milk management system for neonatal ICUs. Its system enables to track milk-bottle inventory, recipes, feeding-order, etc. from mobile-devices; handle first-in-first-out (FIFO) bottle flow, expiry dates notifications, misfeed alerts, and more; provide media-sharing platform for nurses to share photos and videos of NICU babies with their mothers; and offer real time insights into milk-production patterns of lactating mothers. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

Relmada Therapeutics

Seed Round in 2004
Relmada is a clinical-stage pain management company with a diversified portfolio of products for the treatment of chronic pain. It specializes in analgesic Drug Development, Chronic Pain, Pharmaceutical Development, and Opioid Addiction. The company was founded in 2004 and headquartered in Pennsylvania, United States.

Immune Control

Series A in 2005
Immune Control, Inc. was formed in 2001 based on technology developed in the laboratories of Professors Bradford Jameson and Ana Tretiakova, Department of Biochemistry, Drexel University College of Medicine. Initial funding came from Argil Management, LLC, of Boston. In 2003, Stephen Roth, Ph.D., became president and CEO of Immune Control. The Company plans to complete an investigational new drug (IND) application to be submitted to the Food and Drug Agency in 2005. The IND application will propose the use of an already marketed serotonin antagonist in multiple myeloma patients in a small, and relatively short, phase 1/2 clinical trial. If the drug has significant, clinical efficacy against the malignant B cells characteristic of multiple myeloma, they would immediately begin plans for a larger, phase 3 trial. Positive results in the first trial would constitute clinical proof-of-concept for the Company's basic premise-that serotonin antagonists have clinical utility against inappropriately activated immune cells. Another Company goal focuses on proprietary serotonin antagonists that are more potent than those already approved, and that do not cross the blood-brain barrier, making them free of adverse neurological side-effects. Such new chemical entities would be screened for their abilities to bind to specific immunological serotonin receptors, which are now being characterized. The Company has made progress with at least two receptors, one of which has apparently not previously been described. Research on the molecular biology of the receptors is underway at Drexel University College of Medicine, and new chemical entities to be screened for serotonin antagonist activity are being synthesized for the Company. Ultimately, they hope to find compounds that can be used against many hematologic cancers, transplant rejection, and against a host of diseases that are all caused by inappropriate lymphocyte activation. Examples of such diseases are type I diabetes, rheumatoid arthritis, lupus, asthma, and many of the muscular dystrophies. The market size for drugs that treat each of these conditions exceeds a billion dollars. Simultaneously, the Company aggressively protects its intellectual property with patent applications. Novel use applications, novel compound applications, and novel receptor applications are all examples of the Company's existing IP portfolio, which has been licensed exclusively and worldwide to the Company by Drexel University.

Halo Labs

Series B in 2020
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Palvella Therapeutics

Venture Round in 2017
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.

Immunome

Seed Round in 2009
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

Oncora Medical, Inc.

Seed Round in 2016
Oncora Medical, Inc. develops an analytics platform that helps radiation oncologists to use data to provide the care for cancer patients. It provides plug-and-play data extraction tools to integrate clinical information from electronic medical record systems, treatment planning software, and oncology information systems into database; allows physicians to make personalized treatment recommendations for their patients using historical data and predictive analytics; and enables physicians to apply machine learning algorithms to their data to gain information about patient outcomes. Oncora Medical, Inc. was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Group K Diagnostics, Inc.

Seed Round in 2017
Group K Diagnostics, Inc. develops and manufactures a point-of-care diagnostic device for testing liver function. The company offers MultiDiagnostic, a multi-test modular point of care (POC) diagnostic test using paper-based microfluidics which provides three diagnostics with one blood drop. The company also develops a mobile and desktop software that allows patients to upload the picture of the sample card on the application and read the results. Group K Diagnostics, Inc. was founded in 2016 and is based in Philadelphia, Pennsylvania.

Solaris Therapeutics

Seed Round in 2011
Solaris Therapeutics

Oncora Medical, Inc.

Seed Round in 2017
Oncora Medical, Inc. develops an analytics platform that helps radiation oncologists to use data to provide the care for cancer patients. It provides plug-and-play data extraction tools to integrate clinical information from electronic medical record systems, treatment planning software, and oncology information systems into database; allows physicians to make personalized treatment recommendations for their patients using historical data and predictive analytics; and enables physicians to apply machine learning algorithms to their data to gain information about patient outcomes. Oncora Medical, Inc. was incorporated in 2015 and is based in Philadelphia, Pennsylvania.
VenatoRx Pharmaceuticals, Inc., a pharmaceutical company, discovers and develops anti-infective agents. The company provides various antibacterial agents. It focuses on addressing resistant hospital and community bacterial infections, including difficult-to-treat infections caused by MRSA, Pseudomonas spp, and Salmonella spp. The company was founded in 2010 and is based in Malvern, Pennsylvania.

Novira Therapeutics, Inc.

Series A in 2013
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Niiki Pharma

Venture Round in 2011
Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

Temple University

Seed Round in 2010
Full Investment Portfolio Money market funds: 3.09% Corporate bonds and note: 18.26% U.S. government and agency securities: 22.92% Municipal bonds: 0.28% Fixed income funds: 0.92% Equity funds and securities: 25.23% Futures contracts: 0.05% Other: 0.11% Commodity funds: 0.48% Multi-strategy hedge funds: 10.64% Private equity: 0.41% Real estate funds: 2.70% Fixed income funds: 2.13% Equity funds: 12.42% Opportunistic funds: 0.13% Investments carried at equity: 0.23% Founded in 1884, Temple University is a non-profit organisation based in the United States which provides higher education to the students.

Melior Discovery

Venture Round in 2012
Melior Discovery, Inc. develops an in vivo pharmacology platform that identifies novel indications from pre-clinical and development-stage candidates. The company offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal and urology, cardiovascular disease, and dermatology aspects. It serves clients in pharmaceutical and biopharmaceutical industries. The company was founded in 2005 and is based in Exton, Pennsylvania.

Allevi

Seed Round in 2015
Allevi develops tools to design and engineer 3D tissues. It offers desktop 3D bio printers that build functional three dimensional living tissues; bioinks used to collagen and hyaluronic acid; and Bioprint Online that runs in the cloud to design structures, define materials, and monitor prints. The company’s products are used by researchers around the world to perform work in the fields of tissue engineering, regenerative medicine, material science, and cell biology; industrial and pharma companies to test and develop drugs; and educators. Its sells its bioinks online. Allevi was formerly known as BioBots, Inc. The company was incorporated in 2014 and is based in Philadelphia, Pennsylvania.

Olive Devices

Venture Round in 2016
Olive Devices is an assistive device company developing smart glasses to improve communication for deaf and hard of hearing persons.

Merganser Biotech

Series A in 2015
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

Jenrin Discovery, Inc.

Venture Round in 2016
Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

Melior Discovery

Venture Round in 2007
Melior Discovery, Inc. develops an in vivo pharmacology platform that identifies novel indications from pre-clinical and development-stage candidates. The company offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal and urology, cardiovascular disease, and dermatology aspects. It serves clients in pharmaceutical and biopharmaceutical industries. The company was founded in 2005 and is based in Exton, Pennsylvania.

Merganser Biotech

Seed Round in 2012
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

Pillo, Inc.

Series A in 2019
Pillo, Inc. designs and develops a digital care management platform that provides health care plans for adults with chronic conditions at home. The company offers Pillo, a robot, which enable people to manage their health; answer health and wellness questions; connect with healthcare professionals; manage vitamins and medication; and store, dispense, and order refills when required. The company’s robot also sends notifications to the user when medications are missed; sees and hears user to keep them healthy and safe; and syncs with wearables and smart home devices. Pillo, Inc. was incorporated in 2015 and is based in New York, New York.

Avid Radiopharmaceuticals

Series A in 2006
Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

Ceptaris Therapeutics

Series D in 2012
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
Relmada is a clinical-stage pain management company with a diversified portfolio of products for the treatment of chronic pain. It specializes in analgesic Drug Development, Chronic Pain, Pharmaceutical Development, and Opioid Addiction. The company was founded in 2004 and headquartered in Pennsylvania, United States.

MicroMRI

Seed Round in 2005
MicroMRI engages in the development and commercialization of medical devices. It involves in the clinical routine bone assessment of bone micro-architecture using magnetic resonance imaging technology. The company offers imaging coils, image post processing software, and biomarker analysis system for radiologists. It also offers contract research services to the pharmaceutical industry, as well as provides guidance and assistance services.

SansRosa Pharmaceuticals

Venture Round in 2005
Sansrosa Pharmaceutical Development, researches and develops dermatological products for the treatment of rosacea.

NuPathe, Inc.

Seed Round in 2005
NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for neurological and psychiatric disorders. The company’s lead product is Zecuity, which is a sumatriptan iontophoretic transdermal system used for the acute treatment of migraine with or without aura in adults. Its pipeline product candidates include NP201 for the continuous symptomatic treatment of Parkinson's disease; and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The company develops its products using SmartRelief, a proprietary transdermal medication delivery technology based on iontophoresis, a non-invasive method of actively transporting molecules, such as sumatriptan; and Long-Acting Delivery, a biodegradable polymer matrix, which uses medical polymers and an active drug combined to form a small implant for injection just below the skin. NuPathe Inc. was founded in 2005 and is based in Malvern, Pennsylvania. As of February 20, 2014, NuPathe, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.
Galleon Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets treatments for sleep apnea and related breathing control disorders. It offers GAL-021, a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients and patients with sleep apnea; GLN- 21,160, an oral development candidate for sleep apnea; and GAL-044, a small molecule used as a preventative medicine for surgical pain. The company was founded in 2003 and is based in Horsham, Pennsylvania.

Marillion Pharmaceuticals

Seed Round in 2005
Marillion Pharmaceuticals Inc. develops and commercializes pharmaceuticals and therapeutics for the treatment of cancers, inflammatory, and autoimmune diseases.

Solaris Therapeutics

Seed Round in 2011
Solaris Therapeutics

QR Pharma

Debt Financing in 2010
Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.

Enzium, Inc.

Venture Round in 2015
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

Hsiri Therapeutics, LLC

Seed Round in 2015
Hsiri Therapeutics is a development stage pharmaceutical company engaged in the discovery and development of new antibiotics to treat diseases caused by drug resistant bacteria. Hsiri Therapeutics’ efforts are primarily directed at two discrete groups of pathogens – mycobacterial diseases and gram-negative infections. Hsiri Therapetics was formed based on the antibiotic research that originated in the laboratories of Professor Marvin Miller at the University of Notre Dame.

Immunome

Venture Round in 2013
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

Jenrin Discovery, Inc.

Venture Round in 2016
Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

Merganser Biotech

Seed Round in 2013
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

OSSIANIX

Seed Round in 2013
Ossianix Inc., a biotherapeutics company, develops single domain antibodies based on VNAR structure from shark. It produces a shark single domain VNAR phage library and has drug discovery programs in various therapeutic areas. Ossianix Inc. has strategic research collaboration with Lundbeck A/S. The company was founded in 2012 and is based in Philadelphia, Pennsylvania with research laboratories in Stevenage, United Kingdom.

Niiki Pharma

Debt Financing in 2010
Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

Melior Discovery

Venture Round in 2010
Melior Discovery, Inc. develops an in vivo pharmacology platform that identifies novel indications from pre-clinical and development-stage candidates. The company offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal and urology, cardiovascular disease, and dermatology aspects. It serves clients in pharmaceutical and biopharmaceutical industries. The company was founded in 2005 and is based in Exton, Pennsylvania.

Wistar Institute

Seed Round in 2004
The Wistar Institute is the nation’s first independent institution devoted to medical research and training. The Wistar Institute has evolved from its beginnings as an anatomical teaching museum to its present-day status as an international leader in basic biomedical research. In 1972, The Wistar Institute was designated a National Cancer Institute Cancer Center in basic research—a distinction it holds to this day. Wistar discoveries have led to the development of vaccines for rabies, rubella, and rotavirus, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.

Relmada Therapeutics

Venture Round in 2014
Relmada is a clinical-stage pain management company with a diversified portfolio of products for the treatment of chronic pain. It specializes in analgesic Drug Development, Chronic Pain, Pharmaceutical Development, and Opioid Addiction. The company was founded in 2004 and headquartered in Pennsylvania, United States.

Solaris Therapeutics

Seed Round in 2012
Solaris Therapeutics

Novira Therapeutics, Inc.

Debt Financing in 2014
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.
Penn State Health Milton S. Hershey Medical Center is a 551-bed Level I regional trauma center. As Central Pennsylvania’s only academic medical center and home to the Children’s Hospital at Penn State Health Milton S. Hershey Medical Center and Penn State College of Medicine, we are looked to as a resource for the most complex adult and pediatric cases. We have earned ANCC Magnet Recognition, which confirms our commitment to provide a professional environment that supports staff development and quality patient care.

Enzium, Inc.

Seed Round in 2016
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

Protez Pharmaceuticals

Series B in 2005
Protez Pharmaceuticals is a medical research company that discovers, develops, and commercializes antibiotics for difficult-to-treat hospital-based infections. The company focuses on differentiated intravenous and oral small molecule antibiotics to address bacterial resistant, and chronic or recurrent infections. Protez Pharmaceuticals was founded by Christopher M. Cashman in 2003 and is headquartered in Malvern, Pennsylvania.

Halo Labs

Seed Round in 2012
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Mebias Discovery, LLC

Seed Round in 2016
Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Novira Therapeutics, Inc.

Venture Round in 2010
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Anakim

Seed Round in 2012
Anakim Biologics is developing efficiencies and improvements in biologics manufacturing;

Fox Chase Cancer Center

Seed Round in 2005
To prevail over cancer, marshaling heart and mind in bold scientific discovery, pioneering prevention, and compassionate care.

WellSheet, Inc.

Series A in 2020
Wellsheet organizes clinical information with machine learning to predict and visualize the most relevant information for patient care in a physician-friendly format within the existing EHR (Electronic Health Record). By allowing providers to arrive at clinical insights faster, Wellsheet improves early intervention and hospital efficiency, with proven impact in a 10,000 physician health system in NJ. Wellsheet has partnered with major EHR vendors including Epic and Cerner to distribute the Wellsheet product through SaaS-based model for health system customers.

StageMark

Series B in 2007
StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

Ceptaris Therapeutics

Venture Round in 2004
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Melior Discovery

Venture Round in 2011
Melior Discovery, Inc. develops an in vivo pharmacology platform that identifies novel indications from pre-clinical and development-stage candidates. The company offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal and urology, cardiovascular disease, and dermatology aspects. It serves clients in pharmaceutical and biopharmaceutical industries. The company was founded in 2005 and is based in Exton, Pennsylvania.

SansRosa Pharmaceuticals

Seed Round in 2005
Sansrosa Pharmaceutical Development, researches and develops dermatological products for the treatment of rosacea.

QR Pharma

Seed Round in 2013
Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.

Immunome

Venture Round in 2010
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

Renovacor, Inc.

Series A in 2019
Renovacor, Inc., a biopharmaceutical company, develops therapies for the treatment of cardiovascular disease. It develops a gene therapy, which helps to restore cardiac function in patients with heart failure. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.

Imiplex LLC

Seed Round in 2012
Imiplex LLC operates as a biotechnology company that develops protein-based nanotechnology for biosensors, biomaterials, and targeted therapeutic and diagnostic agents. It offers TriPol, a platform that comprises a set of modular components engineered from proteins to provide a flexible system for constructing diverse nanostructures. The company was incorporated in 2003 and is based in Bristol, Pennsylvania.

OSSIANIX

Venture Round in 2014
Ossianix Inc., a biotherapeutics company, develops single domain antibodies based on VNAR structure from shark. It produces a shark single domain VNAR phage library and has drug discovery programs in various therapeutic areas. Ossianix Inc. has strategic research collaboration with Lundbeck A/S. The company was founded in 2012 and is based in Philadelphia, Pennsylvania with research laboratories in Stevenage, United Kingdom.

Immunome

Venture Round in 2013
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

Avid Radiopharmaceuticals

Series C in 2007
Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

Retinapharma Technologies

Seed Round in 2003
Retinapharma Technologies, Inc., is a development stage biotechnology company seeking to develop potential products for the prevention, treatment and diagnosis of vision disorders and eye diseases. Retinapharma is a developer of a range of ophthalmic pharmaceuticals, devices, and consumer eye-care products. Retinapharma Technologies is focused on prevention, diagnosis, and treatment of blinding vision disorders, including early and late-stage age-related macular degeneration, glaucoma, retinitis pigmentosa, and diabetic retinopathy.

Pillo, Inc.

Seed Round in 2017
Pillo, Inc. designs and develops a digital care management platform that provides health care plans for adults with chronic conditions at home. The company offers Pillo, a robot, which enable people to manage their health; answer health and wellness questions; connect with healthcare professionals; manage vitamins and medication; and store, dispense, and order refills when required. The company’s robot also sends notifications to the user when medications are missed; sees and hears user to keep them healthy and safe; and syncs with wearables and smart home devices. Pillo, Inc. was incorporated in 2015 and is based in New York, New York.

Novira Therapeutics, Inc.

Seed Round in 2011
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Dynamis Pharmaceuticals inc

Seed Round in 2004
Dynamis Pharmaceuticals, Inc. is a biopharma company that is developing proprietary small molecule drugs to treat chronic inflammatory diseases. Its proprietary drug candidates inhibit a novel enzymatic pathway that causes the formation of a highly reactive sugar, 3-deoxyglucosone, that stimulates the production of Advanced Glycation End Products (AGEs), oxidative stress and a cascade of inflammatory cytokines.

LumenVu

Seed Round in 2004
LumenVu, Inc., a privately held, development stage company based in Philadelphia.

Halo Labs

Seed Round in 2014
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Niiki Pharma

Debt Financing in 2009
Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

TalexMedical, LLC

Seed Round in 2017
TalexMedical, LLC develops and manufactures a medical device for the treatment of external ear deformities in newborns. The company’s product includes Infantear which is a class I medical device and a nonsurgical ear molding system that is applied in the outpatient setting for replacing surgical ear procedure. Further, the company’s product is customizable, made of soft materials and treats the ear anomaly with one two-week treatment applied to a patient in the first three weeks of life. The company caters primarily to the pediatricians. TalexMedical, LLC was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Jenrin Discovery, Inc.

Venture Round in 2015
Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

Eagle Vision Pharmaceutical

Seed Round in 2010
Eagle Vision Pharmaceutical Corp. offers a novel, clinical-stage, molecular imaging opportunity that enhances the powerful potential of widely available Magnetic Resonance Imaging (MRI) to revolutionize the diagnosis and management of chronic human disease (“Magnetic PET”). SeeMoreTM (EVP1001), a patented, first-in-class, intravenous, manganese-based, intracellular agent that targets metabolically active cells, capitalizes on the high resolution tissue discrimination of MRI to provide superior diagnostic accuracy and earlier assessment of response to therapy for improved patient management. EVP1001 distinguishes healthy from abnormal tissue in a single, noninvasive exam that avoids radiation and radioactive agents. Preclinical and clinical results have validated the technology for broad applications including evaluation of cancer, chronic liver disease and heart disease. Currently, a world-class medical center is conducting advanced clinical trials using EVP1001 to evaluate stem cell therapy for the heart.
Galleon Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets treatments for sleep apnea and related breathing control disorders. It offers GAL-021, a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients and patients with sleep apnea; GLN- 21,160, an oral development candidate for sleep apnea; and GAL-044, a small molecule used as a preventative medicine for surgical pain. The company was founded in 2003 and is based in Horsham, Pennsylvania.

RMH Sciences

Seed Round in 2012
RMH Sciences aims to commercialize newly discovered antibiotics by Dr. Harvey Rubin, University of Pennsylvania Professor of Medicine. One of RMH’s most promising ventures focuses on creating antibiotics to combat hospital acquired bacterial pathogens, a largely unmet need in the current marketplace.

Niiki Pharma

Venture Round in 2011
Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

Innovative Supply Solutions

Venture Round in 2012
Innovative Supply Solutions LLC, a specialty contract service organization, provides clinical drug supply chain management services. Its services include planning/forecasting for API/formulated product needs, project management, budget projection/management, packaging design, inventory management, supply chain coordination and management, IVR/IWR supply design and management, manufacturing coordination, packaging and labeling coordination, distribution coordination, analytical services coordination, product sourcing, material destruction coordination, and consultancy. The company is based in Southampton, Pennsylvania.

Bainbridge Health

Seed Round in 2016
Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.

Hsiri Therapeutics, LLC

Venture Round in 2015
Hsiri Therapeutics is a development stage pharmaceutical company engaged in the discovery and development of new antibiotics to treat diseases caused by drug resistant bacteria. Hsiri Therapeutics’ efforts are primarily directed at two discrete groups of pathogens – mycobacterial diseases and gram-negative infections. Hsiri Therapetics was formed based on the antibiotic research that originated in the laboratories of Professor Marvin Miller at the University of Notre Dame.

Jenrin Discovery, Inc.

Seed Round in 2005
Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

Eagle Vision Pharmaceutical

Seed Round in 2008
Eagle Vision Pharmaceutical Corp. offers a novel, clinical-stage, molecular imaging opportunity that enhances the powerful potential of widely available Magnetic Resonance Imaging (MRI) to revolutionize the diagnosis and management of chronic human disease (“Magnetic PET”). SeeMoreTM (EVP1001), a patented, first-in-class, intravenous, manganese-based, intracellular agent that targets metabolically active cells, capitalizes on the high resolution tissue discrimination of MRI to provide superior diagnostic accuracy and earlier assessment of response to therapy for improved patient management. EVP1001 distinguishes healthy from abnormal tissue in a single, noninvasive exam that avoids radiation and radioactive agents. Preclinical and clinical results have validated the technology for broad applications including evaluation of cancer, chronic liver disease and heart disease. Currently, a world-class medical center is conducting advanced clinical trials using EVP1001 to evaluate stem cell therapy for the heart.

CarePartners Plus, LLC

Seed Round in 2012
CarePartners Plus LLC, a healthcare data and information company, provides patient management solutions. It offers Wellby, a patient engagement technology system that helps people in following steps for better health. The company also provides patient engagement, caregiver management, care coordination, and cost containment solutions for hospitals and physician groups. It serves patients and consumers; employers and associations; government agencies; health insurers; hospital and medical groups; public health system centers; accreditation organizations; health care professionals; educators and researchers; and investors. CarePartners Plus LLC was incorporated in 2009 and is based in Horsham .

Midway Pharmaceuticals

Venture Round in 2008
Midway Pharmaceuticals is a developer of specialty drugs designed to provide beneficial effects in the treatment of gastrointestinal and systemic diseases. The company's specialty drugs focus on finding high molecular weight polymers that can be consumed orally and inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing, enabling healthcare institutions to avail enhanced drugs to protect people's guts from radiation damage and infection.

Marillion Pharmaceuticals

Venture Round in 2005
Marillion Pharmaceuticals Inc. develops and commercializes pharmaceuticals and therapeutics for the treatment of cancers, inflammatory, and autoimmune diseases.

Solaris Therapeutics

Seed Round in 2010
Solaris Therapeutics

Cohero Health

Series A in 2016
Cohero Health offers a proprietary connected health platform for those with respiratory illness. Its sensor-based technology and engaging platform improve medication adherence and care coordination between patients and their care providers. The company offers a suite of tools and technology comprises form flexible inhaler sensors, mobile spirometers, to track real-time adherence and lung function, and a mobile application accessible on iPhone, iWatch, and Android. Cohero Health was founded in 2013 and is headquartered in New York.

BioDetego

Seed Round in 2014
BioDetego is developing, VASPfore, a new biomarker test for selecting cancer treatment protocols. The VASP marker provides information that will direct chemotherapy to high risk patients who will likely benefit from treatment while preventing costly and harmful treatment of low risk patients. BioDetego predicts that the VASPfore will provide payors enormous savings (>$150MM/year) by reducing total treatment costs. The company is led by David Zuzga, Ph.D., Founder and CEO, a research scientist with expertise in cell and molecular biology at La Salle University & Giovanni M. Pitari, M.D., Ph.D. Founder and CSO, a physician and research scientist with expertise in Translational Oncology.

Relmada Therapeutics

Series A in 2012
Relmada is a clinical-stage pain management company with a diversified portfolio of products for the treatment of chronic pain. It specializes in analgesic Drug Development, Chronic Pain, Pharmaceutical Development, and Opioid Addiction. The company was founded in 2004 and headquartered in Pennsylvania, United States.

Immunome

Venture Round in 2011
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

TowerView Health

Seed Round in 2015
TowerView helps the 1 in 3 Americans with a chronic illness manage multiple medications. TowerView’s patients receive pre-filled medication trays that fit into a connected pillbox like a K-Cup into a Keurig coffee machine. Their pillbox can sense when patients forget a dose and automatically sends a text or phone reminder. Unlike other smart pillboxes, they send patients pre-filled medication trays sourced from a pharmacy so patients never have to fill their own pillbox and they work directly with nurses​ to target outreach for non-adherent patients. TowerView is rolling out with Independence Blue Cross in January 2015 and are in advanced discussions with numerous other health plans.

Marillion Pharmaceuticals

Venture Round in 2008
Marillion Pharmaceuticals Inc. develops and commercializes pharmaceuticals and therapeutics for the treatment of cancers, inflammatory, and autoimmune diseases.

CarePartners Plus, LLC

Venture Round in 2015
CarePartners Plus LLC, a healthcare data and information company, provides patient management solutions. It offers Wellby, a patient engagement technology system that helps people in following steps for better health. The company also provides patient engagement, caregiver management, care coordination, and cost containment solutions for hospitals and physician groups. It serves patients and consumers; employers and associations; government agencies; health insurers; hospital and medical groups; public health system centers; accreditation organizations; health care professionals; educators and researchers; and investors. CarePartners Plus LLC was incorporated in 2009 and is based in Horsham .

HealthQx

Series A in 2014
HealthQX specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its VBP analytics platform, ClarityQx, provides the capabilities to design, implement, and monitor the on-going performance of payment models such as episodic, bundled, or accountable care arrangements. The company was founded in 2012 and is based in King Of Prussia, Pennsylvania.

Advaxis

Seed Round in 2003
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.

Avid Radiopharmaceuticals

Series A in 2005
Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

Microbiota

Seed Round in 2013
Microbiota is spun out from university of Pennsylvania, to develop a gut microbiome-based treatment for hyperammonemia.

Cohero Health

Seed Round in 2015
Cohero Health offers a proprietary connected health platform for those with respiratory illness. Its sensor-based technology and engaging platform improve medication adherence and care coordination between patients and their care providers. The company offers a suite of tools and technology comprises form flexible inhaler sensors, mobile spirometers, to track real-time adherence and lung function, and a mobile application accessible on iPhone, iWatch, and Android. Cohero Health was founded in 2013 and is headquartered in New York.

Jenrin Discovery, Inc.

Seed Round in 2012
Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

NexusPharma, Inc.

Seed Round in 2005
NexusPharma is dedicated to the discovery of novel anti-cancer treatments. Novel drug candidates are tested in patient derived xenograft tumor models or patient derived tumor cell lines that are derived from such PDX models – we are creating these models to reflect human disease in the most predictable ways. Please ask us if we could help you in your dicsovery projects with these technologies – creating drug candidates wit a higher chance of success in clinical trials.

Immunome

Venture Round in 2011
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

InfraScan

Seed Round in 2014
InfraScan, Inc., a medical device company, develops, commercializes, and distributes hand-held diagnostic devices for head injury and stroke assessment based on near-infrared (NIR) technology. It offers Infrascanner, a diagnostic device that enables clinicians to detect intracranial bleeding in patients with head trauma; and education and training services. The company’s device is used in hospital and intensive care monitoring, military, screening in remote areas, sports medicine, pediatrics, ambulance services, and other applications. It sells its products through distributors in North America, South America, Africa, Asia, the Middle East, and Europe. InfraScan, Inc. was incorporated in 2004 and is based in Philadelphia, Pennsylvania with research and development lab in Philadelphia, Pennsylvania.

WellTrackONE, LLC

Series A in 2015
WellTrackONE is a population health management company that offers an end-to-end solution to physician offices, ACOs, integrated delivery networks, hospitals, and other physician networks that helps them administer the Medicare Annual Wellness Visit to all their Medicare patients. The company provides clinical risk management services used to offer a comprehensive baseline report for detailing modifiable risk factors, preventative goals, and measurable data. It was founded in 2012 and headquartered in Hilton Head Island, South Carolina.